Baird lowered the firm’s price target on AMN Healthcare to $76 from $90 and keeps a Neutral rating on the shares. The firm said hospitals are still in the post-Covid process of reducing contract nursing levels to optimize workforce levels and they expect the process to continue through Q2 and perhaps stabilization on a sequential basis may emerge in Q3 or Q4.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMN:
- AMN Healthcare Announces Fourth Quarter and Full Year 2023 Results
- AMN Upcoming Earnings Report: What to Expect?
- AMN Healthcare Named One of America’s Greatest Workplaces for Diversity by Newsweek
- AMN Healthcare to Hold Fourth Quarter and Full Year 2023 Earnings Conference Call on Thursday, February 15, 2024
